FindTrial
Sign In

To study the efficacy of mifepristone as compared to oral progesterone in management of heavy menstrual bleeding

Efficacy of mifepristone as compared to oral progestin therapy in management of acute abnormal uterine bleeding: a randomised pilot study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/10/096374
Enrollment
110
Registered
2025-10-23
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N924- Excessive bleeding in the premenopausal period

Interventions

Intervention1: mifepristone: Tab mifepristone 50 mg twice daily per oral for 5 days Control Intervention1: medroxy progesterone acetate: Tab medroxy progesterone acetate 20 mg thrice daily ( total 6

Sponsors

Dr Aditi Kumari
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: REPRODCTIVE AGE FEMALES WILLING TO PARTICIPATE IN STUDY

Exclusion criteria

Exclusion criteria: pregnant patients, local lesions in cervix and vagina, known case of genital tract malignancy, deranged lft, women requiring immediate surgical intervention or UAE

Design outcomes

Primary

MeasureTime frame
Number of patients responding to each treatment in terms of decrease in blood loss within 5 days of starting treatmentTimepoint: Number of patients responding to each treatment in terms of decrease in blood loss within 5 days of starting treatment—

Secondary

MeasureTime frame
Comparison of timr taken for cessation of blood loss in both groupsTimepoint: 14 days;PBAC Score from initiation of treatment till cessation of bleedingTimepoint: 5 days;Efficacy of mifepristone as compared to oral progestin therapy in different etiologies of acute AUB in terms of reduction in PBAC scoreTimepoint: 14 days—

Countries

India

Contacts

Public ContactDr Aditi Kumari

AIIMS New Delhi

drvidushi.kul@gmail.com9891910880

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026